Focal laser ablation for localized prostate cancer

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 791-797

  Lindner, Uri ^a   Lawrentschuk, Nathan ^a   Trachtenberg, John ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; ECHOGRAPHY; ENERGY RESOURCE; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; GLIOMA; HEMATURIA; HUMAN; KIDNEY CARCINOMA; LASER SURGERY; LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION THERAPY; LIVER CELL CARCINOMA; NEODYMIUM LASER; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOID OSTEOMA; PERINEUM INJURY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RADIOTHERAPY; REVIEW;

HUMANS; LASER THERAPY; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 77952578372     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0440     Document Type: Review

References (70)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Whitmore WF Jr. Localised prostatic cancer: Management and detection issues. Lancet 1994;343:1263-1267.
3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
4. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 2007;178:S14-S19.
5. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
6. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-990.
7. Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291: 2713-2719.
8. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009; 101:374-383.
9. Schröder FH. Screening for prostate cancer (PC)-an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 2008; 26:533-541.
10. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening or Prostate Cancer. J Natl Cancer Inst 2003;95:868-878.
11. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006;25:2846-2866.
12. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-1154.
13. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
14. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20:557-566.
15. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
16. Choo R, Klotz L, Danjoux C, et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and=or clinical progression. J Urol 2002;167:1664-1669.
17. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24:46-50. (Pubitemid 43097357)
18. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001;166:1804-1810.
19. Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum 2001;28:551-560.
20. Litwin MS, Lubeck DP, Spitalny GM, et al. Mental health in men treated for early stage prostate carcinoma: A posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 2002;95:54-60.
21. Arredondo SA, Downs TM, Lubeck DP, et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. J Urol 2004;172:1830-1834.
22. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796.
23. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-1335.
24. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2008. Epub ahead of print.
25. Onik G, Narayan P, Vaughan D, et al. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: A new approach to preserving potency. Urology 2002;60:109-114.
26. Ohori M, Eastham JA, Koh H, et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens. J Urol 2006;175(suppl):507-507
27. Onik G. Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: Results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol 2008;31:98-106.
28. Ellis DS, Manny TB Jr, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007;70(suppl 6):9-15.
29. Muto S, Yoshii T, Saito K, et al. Focal therapy with highintensity - focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008;38:192-199. (Pubitemid 351419743)
30. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009;182:1371-1377.
31. Maiman TH. Stimulated optical radiation in ruby. Nature (Lond) 1960;187.
32. Knappe V, Frank F, Rohde E. Principles of lasers and biophotonic effects. Photomed Laser Surg 2004;22:411-417.
33. McGuff PE, Bushnell D, Soroff HS, Deterling RA Jr. Studies of the surgical applications of laser (light amplification by stimulated emission of radiation). Surg Forum 1963;14:143-145.
34. McGuff PE, Deterling RA Jr, Gottlieb LS, et al. Laser surgery of malignant tumors. Dis Chest 1965;48:130-139.
35. McGuff PE, Deterling RA Jr, Gottlieb LS, et al. The laser treatment of experimental malignant tumours. Can Med Assoc J 1964;91:1089-1095.
36. Helsper JT, Sharp GS, Williams HF, Fister HW. The biological effect of laser energy on human melanoma. Cancer 1964;17:1299-1304.
37. Johnson FM, Olson R, Rounds DE. Effects of high-power green laser radiation on cells in tissue culture. Nature 1965;205:721-722.
38. Saks NM, Zuzolo RC, Kopac MJ. Microsurgery of living cells by ruby laser irradiation. AnnNY Acad Sci 1965;122:695-712.
39. Tengroth B. The laser and its use in retinal surgery. Acta Ophthalmol (Copenh) 1966:suppl 84:135.
40. Tengroth B. Laser coagulation risks and advantages. Trans Ophthalmol Soc U K. 1966;86:55-61.
41. Ingram HV. The laser ophthalmoscope coagulator. A preliminary report. Trans Ophthalmol Soc U K 1964;84:453-467.
42. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria. Radiology 2005;235:728-739.
43. Bown SG. Phototherapy in tumors. World J Surg 1983;7:700-709.
44. Germer CT, Roggan A, Ritz JP, et al. Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range. Lasers Surg Med 1998; 23:194-203.
45. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984;10:787-800.
46. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 2009;25:3-20.
47. McNichols RJ, Gowda A, Kangasniemi M, et al. MR thermometry- based feedback control of laser interstitial thermal therapy at 980 nm. Lasers Surg Med. 2004;34:48-55.
48. Vogl TJ, Straub R, Zangos S, et al. MR-guided laser-induced thermotherapy (LITT) of liver tumours: Experimental and clinical data. Int J Hyperthermia 2004;20:713-724.
49. Atri M, Gertner MR, Haider MA, et al. Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J 2009;3:125-130.
50. Vogl TJ, Straub R, Eichler K, et al. Colorectal carcinoma metastases in liver: Laser-induced interstitial thermotherapy- local tumor control rate and survival data. Radiology 2004;230:450-458. (Pubitemid 38133806)
51. Gough-Palmer AL, Gedroyc WM. Laser ablation of hepatocellular carcinoma - A review. World J Gastroenterol 2008;14:7170-7174.
52. Pacella CM, Francica G, Di Lascio FM, et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: A retrospective analysis. J Clin Oncol 2009;27:2615-2621.
53. Ferrari FS, Stella A, Pasquinucci P, et al. Treatment of small hepatocellular carcinoma: A comparison of techniques and long-term results. Eur J Gastroenterol Hepatol 2006;18:659-672.
54. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189:323-328.
55. Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 2006;49:961-969.
56. de Senneville BD, Mougenot C, Moonen CT. Real-time adaptive methods for treatment of mobile organs by MRIcontrolled high-intensity focused ultrasound. Magn Reson Med 2007;57:319-330.
57. de Senneville BD, Mougenot C, Quesson B, et al. MR thermometry for monitoring tumor ablation. Eur Radiol 2007;17:2401-2410.
58. Mougenot C, Quesson B, de Senneville BD, et al. Threedimensional spatial and temporal temperature control with MR thermometry-guided focused ultrasound (MRgHIFU). Magn Reson Med 2009;61:603-614.
59. Puls R, Langner S, Rosenberg C, et al. Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5- year survival. J Vasc Interv Radiol 2009;20:225-234.
60. Schwarzmaier HJ, Eickmeyer F, von Tempelhoff W, et al. MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: Preliminary results in 16 patients. Eur J Radiol 2006;59:208-215.
61. Leonardi MA, Lumenta CB, Gumprecht HK, et al. Stereotactic guided laser-induced interstitial thermotherapy (SLITT) in gliomas with intraoperative morphologic monitoring in an open MR-unit. Minim Invasive Neurosurg 2001;44:37-42.
62. Carpentier A, McNichols RJ, Stafford RJ, et al. Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery 2008;63(suppl 1):S21-29.
63. Papini E, Guglielmi R, Bizzarri G, et al. Treatment of benign cold thyroid nodules: A randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid 2007;17:229-235.
64. Amabile G, Rotondi M, De Chiara G, et al. Low-energy interstitial laser photocoagulation for treatment of nonfunctioning thyroid nodules: Therapeutic outcome in relation to pretreatment and treatment parameters. Thyroid 2006;16: 749-755.
65. Mack MG, Straub R, Eichler K, et al. MR-guided laserinduced thermotherapy in recurrent extrahepatic abdominal tumors. Eur Radiol 2001;11:2041-2046.
66. Rosenberg C, Puls R, Hegenscheid K, et al. Laser ablation of metastatic lesions of the lung: Long-term outcome. AJR Am J Roentgenol 2009;192:785-792.
67. Gangi A, Alizadeh H, Wong L, et al. Osteoid osteoma: Percutaneous laser ablation and follow-up in 114 patients. Radiology 2007;242:293-301.
68. Streitparth F, Gebauer B, Melcher I, et al. MR-guided laser ablation of osteoid osteoma in an open high-field system (1.0 T). Cardiovasc Intervent Radiol 2009;32:320-325.
69. Dick EA, Joarder R, De Jode MG, et al. Magnetic resonance imaging-guided laser thermal ablation of renal tumours. BJU Int 2002;90:814-822.
70. van Esser S, Stapper G, van Diest PJ, et al. Ultrasoundguided laser-induced thermal therapy for small palpable invasive breast carcinomas: A feasibility study. Ann Surg Oncol 2009;16:2259-2263.